LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

LLY

1,008.17

+0.84%↑

JNJ

231.28

+1.24%↑

ABBV

212

+2.62%↑

UNH

399.28

+0.45%↑

AZN

185.47

-0.15%↓

Home・Elenco Azioni・Coherus Oncology Inc

Coherus Oncology Inc

Aperta

SettoreSettore sanitario

1.72 0.58

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.6

Massimo

1.78

Metriche Chiave
By Trading Economics
Entrata	-280M -38M
Vendite	-438K 12M
P/E Media del settore	3.509 51.415
Margine di Profitto	-311.348
Dipendenti	147
EBITDA	7.1M -36M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+382.46% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	33M 292M
Apertura precedente	1.14
Chiusura precedente	1.72

Notizie sul Sentiment di mercato

By Acuity

50%

162 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

0.9209 / 1.05 Supporto e resistenza

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2026, 22:54 UTC

Utili

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2026, 23:51 UTC

Discorsi di Mercato

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mag 2026, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

13 mag 2026, 23:17 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mag 2026, 23:16 UTC

Utili

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mag 2026, 23:15 UTC

Utili

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mag 2026, 23:14 UTC

Utili

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mag 2026, 23:02 UTC

Discorsi di Mercato

Utili

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mag 2026, 22:59 UTC

Discorsi di Mercato

Utili

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mag 2026, 22:24 UTC

Utili

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mag 2026, 22:23 UTC

Utili

Xero FY International Revenue Growth 47%>XRO.AU

13 mag 2026, 22:22 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mag 2026, 22:19 UTC

Utili

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mag 2026, 22:18 UTC

Utili

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mag 2026, 22:16 UTC

Utili

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mag 2026, 22:15 UTC

Utili

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mag 2026, 22:13 UTC

Utili

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mag 2026, 22:12 UTC

Utili

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mag 2026, 22:11 UTC

Utili

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero Did Not Declare a Dividend>XRO.AU

13 mag 2026, 22:10 UTC

Utili

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mag 2026, 22:09 UTC

Utili

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mag 2026, 22:00 UTC

Utili

Cisco to Shed Jobs for All-In AI Push -- Update

13 mag 2026, 21:11 UTC

Utili

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

382.46% in crescita

Previsioni per 12 mesi

Media 8.25 USD 382.46%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.9209 / 1.05Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

162 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.